Skip to Content

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

Proffesor Nir Peled, oncologist, presents in this MEDtalk the efficacy of osimertinib as induction therapy before definitive radiotherapy (RT) in EGFRm stage III patients to induce tumor shrinkage and reduction of the radiation field

Nir Peled

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top